First drug candidate from NIH program acquired by biopharmaceutical company

Potential treatment targets sickle cell disease

A drug candidate developed by researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International’s BioScience business. The drug candidate, Aes-103, is the first specifically developed to target the underlying molecular mechanism of sickle cell disease. Baxter now will advance the clinical development activities required for regulatory approval and commercialization.

Read more View All News

This page was last updated on Friday, January 21, 2022